The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant… The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…

The FDA Is Trying To Make Corporate Free Speech Situational

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images)

Getty Images

While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future.

Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit.

The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music.

Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant to create a healthier future, they made sure to downplay or outright deny their achievements?

Makary pats his FDA and Trump administration on the back for acting to “rein in misleading pharmaceutical ads,” but it’s the equivalent of the Trump administration demanding that pharmaceutical companies demean their capabilities. How could the allegedly pro-business Trump administration make such a demand, one that no other politician or business would ever be expected to abide?

To which Makary and his defenders might reply that with pharmaceutical drugs, the rules should be different. Since health and health outcomes are on the line, sometimes of the life and death variety, pharmaceutical companies must follow a different set of rules. Except that pharmaceutical companies already do. And Makary knows this truth well.

As evidenced by the years of work and billions spent just to attain drug approval, pharmaceutical companies go to enormous lengths to get their innovations into the marketplace. Their drugs are FDA approved. Which is the point, or should be.

In seeking greater policing of drug advertising, Makary is adding another layer to the already substantial oversight provided by the FDA, oversight that has yet more layers. While pharmaceutical companies can advertise their FDA approved drugs, would-be patients can still only attain them insofar as they’re prescribed by a doctor. Which of course answers Makary’s odd critique that drugmakers are targeting potential users with “misleading ads.” Really? How?

Lest Makary forget, the ads are yet again for FDA approved drugs that are once again only accessible with a doctor-signed prescription. Which raises a basic question: if the FDA is doing its job in the approval process, and doctors are doing their jobs, why the limits on the free speech rights of pharmaceutical companies to advertise the health possibilities that come with their innovations? Why indeed.

Absent a compelling answer from Makary, it’s difficult to find a compelling reason for the Trump administration to make free speech situational. Pharmaceutical companies prosper by improving our lives. Let them advertise their capacity to do just that.

Source: https://www.forbes.com/sites/johntamny/2025/09/17/the-fda-is-trying-to-make-corporate-free-speech-situational/

Market Opportunity
SynFutures Logo
SynFutures Price(F)
$0.005467
$0.005467$0.005467
-0.88%
USD
SynFutures (F) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Daily market key data review and trend analysis, produced by PANews.
Share
PANews2025/04/30 13:50
ZEC Rally and G Coin — Two Altcoin Setups Worth Watching

ZEC Rally and G Coin — Two Altcoin Setups Worth Watching

The post ZEC Rally and G Coin — Two Altcoin Setups Worth Watching appeared on BitcoinEthereumNews.com. The crypto market has started the week on a bullish footing
Share
BitcoinEthereumNews2026/03/19 00:58
IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

The post IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge! appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 18:00 Discover why BlockDAG’s upcoming Awakening Testnet launch makes it the best crypto to buy today as Story (IP) price jumps to $11.75 and Hyperliquid hits new highs. Recent crypto market numbers show strength but also some limits. The Story (IP) price jump has been sharp, fueled by big buybacks and speculation, yet critics point out that revenue still lags far behind its valuation. The Hyperliquid (HYPE) price looks solid around the mid-$50s after a new all-time high, but questions remain about sustainability once the hype around USDH proposals cools down. So the obvious question is: why chase coins that are either stretched thin or at risk of retracing when you could back a network that’s already proving itself on the ground? That’s where BlockDAG comes in. While other chains are stuck dealing with validator congestion or outages, BlockDAG’s upcoming Awakening Testnet will be stress-testing its EVM-compatible smart chain with real miners before listing. For anyone looking for the best crypto coin to buy, the choice between waiting on fixes or joining live progress feels like an easy one. BlockDAG: Smart Chain Running Before Launch Ethereum continues to wrestle with gas congestion, and Solana is still known for network freezes, yet BlockDAG is already showing a different picture. Its upcoming Awakening Testnet, set to launch on September 25, isn’t just a demo; it’s a live rollout where the chain’s base protocols are being stress-tested with miners connected globally. EVM compatibility is active, account abstraction is built in, and tools like updated vesting contracts and Stratum integration are already functional. Instead of waiting for fixes like other networks, BlockDAG is proving its infrastructure in real time. What makes this even more important is that the technology is operational before the coin even hits exchanges. That…
Share
BitcoinEthereumNews2025/09/18 00:32